Breast Cancer

Articles

In a retrospective review published in NPJ Breast Cancer, data indicate that omitting radiation therapy results in decreased overall survival in patients with stage I HER2-positive breast cancer.

Radiation Therapy Omission Not Advised in Early-Stage HER2+ Breast Cancer

Pyrotinib plus capecitabine to treat patients with HER2-positive metastatic breast cancer saw a statistically significant improvement in progression-free survival.

Pyrotinib and Capecitabine Combo Improved PFS Compared to Lapatinib Plus Capecitabine for HER2-Positive Breast Cancer

Sara A. Hurvitz, MD, FACP, of the University of California, Los Angeles, discussed a number of emerging novel therapies with the potential to treat patients with HER2-positive metastatic breast cancer in the third-line setting.

Potential Novel Therapies Emerge for Third-Line Setting in Patients with HER2+ Metastatic Breast Cancer

At the Miami Breast Cancer Conference, Debu Tripathy, MD, reviewed adaptive therapy for the adjuvant treatment of patients with HER2-positive, early-stage breast cancer.

Adaptive Therapy Approach in HER2+ Early Breast Cancer May Improve Outcomes, Expert Says

The combination of liposomal doxorubicin, docetaxel, and trastuzumab with metformin produced positive activity and an acceptable safety profile as neoadjuvant treatment for HER2-positive breast cancer.

Drug Combination With Metformin Showed Positive Activity and Safety for Patients with HER2-Positive Breast Cancer

The PHERGain II trial will investigate the treatment of patients with early HER2-positive breast cancer using a chemotherapy-free treatment approach of trastuzumab plus pertuzumab.

PHERGain II Trial Launched to Examine Chemotherapy-Free Treatment for Patients With HER2+ Breast Cancer

Videos

Recommendations for managing 2 patient cases specific to HER2-positive metastatic breast cancer and optimizing therapy for specific patient populations within the HER2-positive space based on emerging treatments and changes to standards of care.

Relapsed/Refractory HER2+ Metastatic Breast Cancer

Results from the phase 3 SOPHIA trial demonstrated that margetuximab plus chemotherapy had an acceptable safety profile which was comparable to that observed with trastuzumab plus chemotherapy.

Margetuximab Plus Chemo Improves PFS Versus Trastuzumab/Chemo in ERBB2+ Advanced Breast Cancer

The randomized, open-label, phase 3 FeDeriCa trial tested the safety profile of pertuzumab and trastuzumab plus hyaluronidase-zzxf in 500 patients with HER2-positive early breast cancer.

Subcutaneous Pertuzumab and Trastuzumab Combo for HER2-Positive Early Breast Cancer Shown as Noninferior to Intravenous Infusions

Register for CancerNetwork's live, interactive event featuring leaders in oncology reviewing and discussing patient cases in breast cancer.

HER2-Positive Breast Cancer | Topics